Skip to main content
SpringerLink
Log in

Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels

  • Original Investigations
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

The percentage occupation of striatal dopamine D2 receptors has been evaluated in 25 patients using76Br-bromospiperone positron emission tomography (PET) and prolactin plasma levels (PRL) during oral neuroleptic treatment (11 studies), 1–90 days following discontinuation of such treatment (16 studies), and 1–120 days after last intramuscular administration of depot neuroleptics (nine studies). The PET-estimated occupation was highly significantly correlated in a sigmoîd-like fashion to the logarithm of the chlorpromazine-equivalent dose of oral neuroleptics (suggesting a strict dose-occupation relationship during oral neuroleptic treatment and supporting the D2-mediated hypothesis of neuroleptic action), while PRL was weakly related to daily dosage. Following withdrawal, return to normal receptor availability, as estimated by PET, occurred within 5–15 days (suggesting that protracted effects of neuroleptics after withdrawal are not due to sustained D2 receptor occupation), but PRL values fell even more rapidly. Efficient treatment with depot neuroleptics resulted in marked PET-estimated D2 receptor occupation, stable over the whole 4-week drug-administration interval, suggesting that longer intervals could be appropriate; PRL values bore no relationship to PET-estimated occupation, indicating variable intersubject tolerance to neuro-endocrine dopamine blockade. Overall, PET was much more sensitive than PRL to estimate striatal D2 receptor occupation in vivo.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • American Psychiatric Association (1980) Diagnostic and statistical manual of mental disorders IIIrd edn. Washington DC, APA

    Google Scholar 

  • Arnett CD, Fowler JS, Wolf AP, Schuie CY, McPherson DW (1985)18F-N-Methylspiroperidol: the radioligand of choice for PET studies of the dopamine receptor in human brain. Life Sci 36:1359–1366

    Google Scholar 

  • Bagdy G, Perenyi A, Frecska E, Revai K, Pappa Z, Fekete MIK, Arato M (1985) Decrease in dopamine, its metabolites, and noradrenaline in cerebrospinal fluid of schizophrenic patients after withdrawal of long-term neuroleptic treatment. Psychopharmacology 85:62–64

    Google Scholar 

  • Baron JC (1987) In vivo study of central receptors in man using PET. In: S Tucek (ed) Synaptic transmitters and receptors. Academic, Prague, pp 80–88

    Google Scholar 

  • Baron JC, Mazière B, Loc'h C, Cambon H, Sgouropoulos P, Bonnet AM, Agid Y (1986) Loss of striatal76Br-bromospiperone binding sites demonstrated by positron tomography in progressive supranuclear palsy. J Cereb Blood Flow Metab 6:131–136

    Google Scholar 

  • Barone D, Luzzani F, Assandri A, Galliani G, Mennini T, Garattini S (1985) In vivo stereospecific3H-spiperone binding in rat brain: characteristics, regional distribution, kinetics and pharmacological properties. Eur J Pharmacol 116:63–74

    Google Scholar 

  • Biomerieux Laboratory Reagents and Instruments (1988)125I-prolactin coatria Radioimmunoassay, Booklet of Instructions, RCS, Lyon (France)

    Google Scholar 

  • Blin J, Baron JC, Cambon H, Bonnet AM, Dubois B, Loc'h C, Mazière B, Agid Y (1989) Striatal dopamine D2 receptors in tardive dyskinesia: a PET study. J Neurol Neurosurg Psychiatry (in press)

  • Boyson SJ, McGonigle P, Luthin GR, Wolfe BB, Molinoff PB (1988) Effects of chronic administration of neuroleptic and anticholinergic agents on densities of D2 dopamine and muscarinic cholinergic receptors in rat striatum. J Pharmacol Exp Ther 244:987–993

    Google Scholar 

  • Burt DR, Creese I, Snyder SH (1976) Properties of3H-haloperidol and3H-dopamine binding associated with dopamine receptors in calf brain membranes. Mol Pharmacol 12:800–812

    Google Scholar 

  • Cambon H, Baron JC, Boulenger JP, Loc'h C, Zarifian E, Mazière B (1987) In vivo assay for neuroleptic receptor binding in the striatum: positron tomography in humans. Br J Psychiatry 151:824–830

    Google Scholar 

  • Campbell A, Baldessarini RJ, Teicher MH, Kula NS (1985) Prolonged antidopaminergic actions of single doses of butyrophenones in the rat. Psychopharmacology 87:161–166

    Google Scholar 

  • Creese I, Burt DR, Snyder SH (1976) Dopamine receptors and average clinical doses. Science 194:546

    Google Scholar 

  • Dahl SG, Halps PA (1987) Pharmacokinetic and pharmacodynamic factors causing variability in response to neurolepitc drugs. In: Dahl, Gran, Paul, Potter (eds) Clinical pharmacology in psychiatry. Springer, Berlin Heidelberg New York Tokyo, pp 266–274

    Google Scholar 

  • Davis JM, Andriukaitis S (1986) The natural course of schizophrenia and effective maintenance drug treatment. J Clin Psychopharmacol 6:25–105

    Google Scholar 

  • Davis JM, Vogel C, Gibbons R, Parkovic I, Zhang M (1984) Pharmaccendocrinology of schizophrenia. In: Brown GM, et al. (eds) Neuroendocrinology and psychiatric disorder. Raven Press, New York, pp 29–53

    Google Scholar 

  • De Lean A, Munson PJ, Rodbard D (1978) Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol 235(2):E97-E102

    Google Scholar 

  • Farde L, Wiesel FA, Hall H, Halldin C, Stone-Elander S, Sedvall G (1987) No D2 receptor increase in PET study of schizophrenia. Arch Gen Psychiatry 44:671

    Google Scholar 

  • Farde L, Wiesel FA, Halldin C, Sedvall G (1988a) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45:71–76

    Google Scholar 

  • Farde L, Wiesel FA, Jansson P, Vippfeldt G, Whilen A, Jedvall G (1988b) An open-label trial of raclopride in acute schizophrenia: confirmation of D2 dopamine receptor occupancy by PET. Psychopharmacology 94:1–7

    Google Scholar 

  • Ferrero P, Vaccarino F, Guidotti A, Costa E, Di Chiro G (1983) In vivo modulation of brain dopamine recognition sites: a possible model for emission computed tomography studies. Neuropharmacology 22:791–795

    Google Scholar 

  • Forrest IS, Fox J, Green DE, Melikian AP, Serra MT (1974) Total excretion of3H-chlorpromazine in chronically-dosed animals: balance sheet. In: Forrest IS, Carz CJ, Usdin E (eds) The phenothiazines and structurally related drugs. Raven Press, New York, pp 347–356

    Google Scholar 

  • Frost JJ, Mayberg HS, Fisher RS, Douglass KH, Dannals RF, Links JA, Wilson AA, Ravert HT, Rosenbaum AE, Snyder SH, Wagner HN (1988) Mu-opiate receptors measured by positron emission tomography in temporal lobe epilepsy. Ann Neurol 23:231–237

    Google Scholar 

  • Gunnet JW, Moore KE (1988) Neuroleptics and neuroendocrine function. Annu Rev Pharmacol Toxicol 28:347–366

    Google Scholar 

  • Hagglund J, Aquilonius SM, Eckernas SA, Hartrig P, Lundquist H, Gullberg P, Langstrom B (1987) Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using11C-N-Methyl-Spiperone. Acta Neurol Scand 75:87–94

    Google Scholar 

  • Hershon HI, Kennedy PF, McGuire RJ (1972) Persistence of extrapyramidal disorders and psychiatric relapse after withdrawal of long-term phenothiazine therapy. Br J Psychiatry 120:41–50

    Google Scholar 

  • Inoue Y, Wagner HN Jr, Wong DE, Links JM, Frost JJ, Dannals RF, Rosenbaum AE, Takeda K, DiChiro G, Kuhar MJ (1985) Atlas of dopamine receptor images (PET) of the human brain. J Comput Assist Tomogr 9:129–140

    Google Scholar 

  • Jenner P, Marsden CD (1983) Neuroleptics and tardive dyskinesia. In: Coyle JT, Enna SJ (eds) Neuroleptics neurochemical, behavioral and clinical perspectives. Raven Press, New York, pp 223–253

    Google Scholar 

  • Jorgensen A (1986) Metabolism and pharmacokinetics of antipsychotic drugs. Prog Drug Metab 9:111–174

    Google Scholar 

  • Kashihara K, Sato M, Fujiwara Y, Harada T, Ogawa T, Otsuki S (1986) Effects of intermittent and continuous haloperidol administration on the dopaminergic system in the rat brain. Biol Psychiatry 21:650–656

    Google Scholar 

  • Keller HH, Schaffner R, Haefely W (1976) Interaction of benzodiazepines with neuroleptics at central dopamine neurons. Naunyn Schmiedeberg's Arch Pharmacol 294:1–7

    Google Scholar 

  • Krska J, Sampath G, Shah A, Sori SD (1986) Radioreceptor assay of serum neuroleptic levels in psychiatric patients. Br J Psychiatry 148:187–193

    Google Scholar 

  • Laduron PM, Janssen PFM, Leysen JE (1978) Characterization of specific in vivo binding of neuroleptic drugs in rat brain. Life Sci 23:581–586

    Google Scholar 

  • Landaw EM, Distefano JJ (1984) Multiexponential, multicompartimental and noncompartmental modeling. II. Data analysis and statistical considerations. Am J Physiol 246(5):R665-R677

    Google Scholar 

  • Leysen JE (1984) Receptors for neuroleptic drugs. In: Burrows GD, Werry JS (eds) Advances in human psychopharmacology, vol III. JAI Press, Greenwich Connecticut, pp 315–356

    Google Scholar 

  • Mahju MA, Maickel RP (1969) Accumulation of phenothiazine tranquilizers in rat brain and plasma after repeated dosage. Biochem Pharmacol 18:2701–2710

    Google Scholar 

  • Marsden CD, Tarsy D, Baldessarini RJ (1975) Spontaneous and drug-induced movement disorders in psychotic patients. In: Benson DF, Blumer D (eds) Psychiatric aspects of neurologic disease. Grune and Stratton, New York, pp 219–265

    Google Scholar 

  • Martinot JL, Peron-Magnan P, Huret JD, Mazoyer B, Baron JC, Boulenger JP, Mazière B, Caillard V, Loo H, Syrota A (1989) Striatal D2 dopaminergic receptors assessed in vivo by positron emission tomography and76Br-bromospiperone in untreated schizophrenics Am J Psychiatry (in press)

  • Mazière B, Loc'h C, Hantraye P, Guillon R, Duquesnoy N, Soussaline F, Naquet R, Comar D, Mazière M (1984)76Br-Bromospiroperidol: a new tool for quantitative in vivo imaging of neuroleptic receptors. Life Sci 35:1349–1356

    Google Scholar 

  • Mazière B, Loc'h C, Baron JC, Sgouropoulos P, Duquesnoy N, D'Antona R, Cambon H (1985) In vivo quantitative imaging of dopamine receptors in human brain using positron emission tomography and76Br-bromospiperone. Eur J Pharmacol 114:267–272

    Google Scholar 

  • Meltzer HY, Kane JM, Kolakowska T (1983) Plasma levels of neuroleptics, prolactin levels and clinical response. In: Coyle JT, Enna SJ (eds) Neuroleptics: neurochemical, behavioral and clinical perspectives. Raven Press, New York, pp 255–279

    Google Scholar 

  • Mihda KK, Hawes EM, Hubbard JW, Korchinski ED, McKay G (1987) The search for correlations between neuroleptic plasma levels and clinical outcome: a critical review. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 1341–1351

    Google Scholar 

  • Miller LG, Greenblatt DJ, Barnhill JG, Shader RI (1988) Chronic benzodiazepine administration: tolerance is associated with benzodiazepine receptor down regulation and decreased γ-aminobutyric acid A receptor function. J Pharmacol Exp Ther 246:170–176

    Google Scholar 

  • Morgan DG, Marcusson JO, Nyberg P, Wester P, Winblad B, Gordon MN, Finch CE (1987) Divergent changes in D1 and D2 dopamine binding sites in human brain during aging. Neurobiol Aging 8:195–201

    Google Scholar 

  • Norman TR, Marriott PF, Kimber NM, Burrows GD (1987) Plasma prolactin and fluphenazine concentrations in patients receiving fluphenazine decanoate: stability over injection intervals. Int Clin Psychopharmacol 2:299–305

    Google Scholar 

  • Ortiz A, Gershon S (1987) Plasma levels of neuroleptics in clinical treatment of acute psychotic states. ISI Atlas of Science (Pharmacology) 1:60–62

    Google Scholar 

  • Owen F, Poulter M, Marshal RD, Crow TJ, Veall N, Zanelli GD (1983)77Br-p-bromospiperone: a ligand for in vivo labelling of dopamine receptors. Life Sci 33:765–768

    Google Scholar 

  • Perlmutter JS, Kilbourn MR, Raichle ME, Welch MT (1987) PET demonstration of upregulation of radioligand-receptor binding in human MPTP-induced Parkinsonism. J Cereb Blood Flow Metab [Suppl 1] 7:371

    Google Scholar 

  • Peroutka SJ, Snyder SH (1980) Relationship of neuroleptic drug effects at brain dopamine, serotonin,-adrenergic, and histamine receptors to clinical potency. Am J Psychiatry 137:1518–1522

    Google Scholar 

  • Richelson E, Nelson A (1984) Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur J Pharmacol 103:197–204

    Google Scholar 

  • Saelens JK, Simke JP, Neale SE, Weeks BJ, Selwyn M (1980) Effects of haloperidol andd-amphetamine on in vivo3H-spiroperidol binding in the rat forebrain. Arch Int Pharmacodyn 246:98–107

    Google Scholar 

  • Seeman P, Bzowej NH, Guan HC, Bergeron C, Becker LE, Reynolds GP, Riederer P, Jellinger K, Watanabe S, Tourtelotte WW (1987a) Human brain dopamine receptors in children and aging adults. Synapse 1:399–404

    Google Scholar 

  • Seeman P, Bzowej NH, Guan HC, Bergeron C, Reynolds GP, Bird ED, Riederer P, Jellinger K, Tourtelotte WW (1987b) Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's disease. Neuropsychopharmacology 1:5–15

    Google Scholar 

  • Severson JA, Marcusson J, Winblad B, Finch CE (1982) Agecorrelated loss of dopaminergic binding sites in human basal ganglia. J Neurochem 39:1623–1631

    Google Scholar 

  • Smith M, Wolf AP, Brodie JD, Arnett CD, Barouche F, Schiue CY, Fowler JS, Russel JAG, MacGregor RR, Wolkin A, Angrit B, Rotrosen J, Peselow E (1988) Serial18F-N-methylspiroperidol PET studies to measure changes in antipsychotic drug D2 receptor occupancy in schizophrenic patients. Biol Psychiatry 23:653–663

    Google Scholar 

  • Sunderland T, Cohen BM (1987) Blood to brain distribution of neuroleptics. Psychiatry Res 20:299–305

    Google Scholar 

  • Wong DF, Wagner HN Jr, Dannals RF, Links JM, Frost JJ, Ravert HT, Wilson AA, Rosenbaum AE, Gjedde A, Douglass KH, Petronis JD, Folstein MF, Toung JKT, Burns HD, Kuhar MJ (1984) Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science 226:1393–1396

    Google Scholar 

  • Wong DF, Wagner HN, Tune LE, Dannals RF, Pearlsson GD, Links JM, Tahminga CA, Broussole EP, Ravert HT, Wilson AA, Thomas, Toung JK, Malat J, Williams JA, Otuama LA, Snyder SH, Kuhar MJ, Gjedde A (1986) Posttron emission tomography reveals elevated D2, dopamine receptors in drugnaive schizophrenics. Science 234:1559–1563

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Départment de Biologie (Pr. Syrota), Service Hospitalier Frédéric Joliot, CEA, F-91406, Orsay, France

    J. C. Baron, J. L. Martinot, H. Cambon, J. Blin, J. D. Huret, C. Loc'h & B. Maziere

  2. Centre Psychiatrique Esquirol (Pr. Zarifian), and INSERM Unit #320, F-14033, Caen, Cedex, France

    J. P. Boulenger & V. Caillard

  3. Service de Thérapeutique et de Santé Mentale (Pr. Loo), Hôpital Sainte-Anne, F-75014, Paris, France

    M. F. Poirier

Authors
  1. J. C. Baron
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. L. Martinot
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Cambon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. P. Boulenger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. F. Poirier
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. V. Caillard
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Blin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. D. Huret
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C. Loc'h
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. B. Maziere
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baron, J.C., Martinot, J.L., Cambon, H. et al. Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology 99, 463–472 (1989). https://doi.org/10.1007/BF00589893

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00589893

Key words

Search

Navigation